Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
ACS Applied Materials & Interfaces|August 10, 2021
Facile Synthesis of Graphene with Fast Ion/Electron Channels for High-Performance Symmetric Lithium-Ion CapacitorsYongcheng Xiao, Jing Liu, Dong He, et al.
Thrombosis and Haemostasis|December 24, 2003
The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesisMahasen Saleh, Weimin Peng, Mary Ann Quinn-Allen, et al.
Leukemia & Lymphoma|July 8, 2024
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysisJames J Wu, Sally W Wade, Taha Itani, et al.
Journal of Medical Economics|May 25, 2022
Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in EnglandSvenja Petersohn, Gilles Salles, Michael Wang, et al.
European Urology|February 8, 2016
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate CancerScott T Tagawa, Edwin M Posadas, Justine Bruce, et al.
Advances in Therapy|March 18, 2024
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase InhibitorGilles Salles, Jenny M H Chen, Ina Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancerHoward I Scher, Glenn Heller, Arturo Molina, et al.
European Urology|June 10, 2019
Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus PrednisoneEleni Efstathiou, John W Davis, Louis Pisters, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 28, 2015
VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo EfficacyHilary Highfield Nickols, Joannes P Yuh, Karen J Gregory, et al.
ACS Chemical Neuroscience|September 24, 2024
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)Julie L Engers, Logan A Baker, Sichen Chang, et al.
Pageof 4